|
Of progressive weakness in older people, IBM should be an important diagnostic consideration. Treatment-resistant `polymyositis' in patients over 50 years of age is often IBM. If there is no histological confirmation, the diagnostic criteria allow for a category of `possible IBM' [4]. Sometimes, the diagnosis is missed because of the slow progression of the disease and a lack of suspicion on the part of physicians. The following case report and literature review will explore many of these issues.
L. Moldes, M.D. Pealver, L. Rodriguez-Otero, P.A. Romero, A. GmezRial, S. Cortizo, B.J. Regueiro. Laboratory of Microbiology, University Hospital Complex of Santiago do Compostela, Santiago de Compostela, Spain Candidemia is a clinically important disease which has increased in incidence world wide in recent decades. We have studied species pattern, antifungal susceptibility and association with colinization infetion in others body sites, of Candida spp recovered from blood cultures in University Hospital Complex of Santiago de Compostela along 2005. The patients must have had at least one blood culture positive for Candida spp and clinical evidence of sepsis. Yeast isolates were identified by microscopic and biochemical methods API, BioMerieux; Vitek 2, France and Chrom Agar, Becton Dickinson, USA ; . MICs was determinated by E-test Abbiodisk Sweeden ; . During this period we detected 58 patients with candidemia 35 male and 23 female ; . The average age was 62.10 years range, 0 to 86 ; . All the patients had some risk factors: intensive care 43.10% ; , antimicrobial treatment within 2 weeks prior to blood yeast detection 91.38% ; , haematological disase or solid tumour 10.34% ; . In 15 25.86% ; patients Candida were recoverd only from blood. In the others 43, from blood and others localitations: catheter 18 31% respi.
VSD indicates ventricular septal defect; ASD, atrial septal defect; AVSD, atrioventricular septal defect; TGV, transposition of the great vessels; PDA, patent ductus arteriosus; SAP, systemic arterial pressure; and PAP, pulmonary arterial pressure. * Post-Senning procedure with VSD left open.
'100%': '800px' gynecologic oncology volume 78, issue 1 , july 2000, pages 76-77 abstract gemcitabine in cervical cancer gynecologic oncology , volume 90, issue 2, supplement 1 , august 2003 , pages s8-s15 david mutch and jeffrey bloss abstract objective recurrent and advanced cervical cancers are associated with high mortality and a lack of effective treatment options, especially for women who are poor candidates for surgery or radiation therapy.
Essentially uniformly labeled with BrdUrd Figs. 6 and 7 ; to the large control tumors with necrotic centers Figs. 1 and 2 ; . Standardizing these tissues to 100 mm2 reflects these morphological observations Table 2 ; . HCT-116 tumor growth was inhibited by 90% after treatment with gemcitabine Table 1 ; , coupled with a 26% reduction in the percentage of proliferating cells and a significant increase in the percentage of apoptotic cells, which contribute to the reduction in tumor growth 14 ; . The percentage of viable tumor after gemcitabine treatment was 85%, indicating that most of the remaining tumor was viable after drug treatment. Similar findings were present in the NCIH460 mitomycin C-treated tumors. The other drug-treated tumors did not exhibit any significant changes in percent area of tumor viability or necrosis, as shown in Table 2. Gemcitabine was clearly inactive against the NCI-H460 tumors in all parameters measured. Mitomycin C reduced the NCI-H460 tumor necrotic area. Clearly, the 50-mg kg day dose of cyclophosphamide had activity against the HCT-116 tumors, with a significant re.
Naltrexone is recommended as a treatment option for people who have been opioid dependent but who have stopped using opioids, and who are highly motivated to stay free from the drugs in an abstinence programme. It should only be given to people who have been told about the problems associated with treatment, and with proper supervision. Treatment with naltrexone should be given as part of a support programme to help the person manage their opioid dependence. NICE Guidance: : tinyurl 2zghj8 Quick Reference Guide: : tinyurl 2yfs4u Understanding NICE Guidance: : tinyurl yqh87l Costing Statement: : tinyurl 2yueje Drug Misuse Methadone and Buprenorphine TA115 24th January 2007 ; Methadone and buprenorphine given as a tablet or a liquid ; are recommended as treatment options for people who are opioid dependent. A decision about which is the better treatment should be made on an individual basis, in consultation with the person, taking into account the possible benefits and risks of each treatment for that particular person. If both drugs are likely to have the same benefits and risks, methadone should be given as the first choice. NICE Guidance: : tinyurl 26m927 Quick Reference Guide: : tinyurl 27zev8 Understanding NICE Guidance: : tinyurl ypwxe8 Costing Template and Costing Report: : tinyurl yw58jf Cryotherapy for Renal Cancers IPG207 24th January 2007 ; The National Institute for Health and Clinical Excellence NICE ; has issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on cryotherapy for renal cancers. Renal cancer occurs in the lining of the very small tubes in the kidney. Cryotherapy uses cold temperature to destroy cancer cells through the insertion of a freezing probe into the tumour. Guidance: : tinyurl yoshrf Understanding NICE Guidance: : tinyurl yu5k3l Consultation Comments Table: : tinyurl 23qenc Colourectal Cancer Metastatic ; Bevacizumab & Cetuximab TA118 24th January 2007 ; Bevacizumab in combination with 5-fluorouracil plus folinic acid, with or without irinotecan, is not recommended for the first-line treatment of metastatic colourectal cancer. Cetuximab in combination with irinotecan is not recommended for the secondline or subsequent treatment of metastatic colourectal cancer after the failure of an irinotecan containing chemotherapy regimen. People currently receiving bevacizumab or cetuximab should have the option to continue therapy until they and their consultants consider it appropriate to stop. Guidance: : tinyurl 23xx38 Quick Reference Guide: : tinyurl 2bd6fy Understanding NICE Guidance: : tinyurl 26pxb4 Costing Statement: : tinyurl yvqdds Breast Cancer Gemcitabine TA116 24th January 2007 ; Gemcitabine, which is combined with another medicine called paclitaxel to treat metastatic breast cancer, is only recommended as a possible treatment for people with metastatic breast cancer in situations where two other treatments could also be used as alternatives. Other treatments that doctors could use in the same situation are a medicine called docetaxel given on its own ; and docetaxel combined with another medicine called capecitabine. Guidance: : tinyurl 2bkg5q Quick Reference Guide: : tinyurl 26lbw8 Understanding NICE Guidance: : tinyurl 227fj3 Audit Criteria: : tinyurl yv85kf Costing Statement: : tinyurl 2hn2w4 NICE Citizens Council to discuss 'only in research' recommendations 22nd January 2007 ; The Citizens Council of the National Institute for Health and Clinical Excellence NICE ; , which provides public input into the Institute's work, will hold its next meeting in London from 25 to 27 January 2007. At this meeting the Citizens Council will be asked for its views on when it is appropriate for NICE to recommend a treatment or intervention to be used only in the context of research. The Citizens Council will hear evidence from speakers covering all aspects of this topic before thoroughly discussing and deliberating on these issues. : tinyurl 2zhm6f and gemifloxacin.
Adamson PC, Widemann BC, Reaman GH, Seibel NL, Murphy RF, Gillespie AF, Balis FM. A phase I trial and pharmacokinetic study of 9-cis-retinoic acid ALRT 1057 ; in pediatric patients with refractory cancer. Clin Cancer Res. 7 10 ; : 3034-9, 2001. Dinndorf P, Krailo M, Liu-Mares W, Frierdich S, Sondel P, Reaman G: Phase I trial of anti-B4-blocked ricin anti-B4-bR ; in pediatric leukemia and lymphoma. J Immunother 24 6 ; : 511-6, 2001. Wells RJ, Reid JM, Ames MM, Mares WL, Krailo MD, Seibel NL, Mosher R, Reaman GH, Wiersma SR. Phase I trial of cisplatin and topotecan in children with recurrent solid tumors. J Pediatr Hematol Oncol 24 2 ; : 89-93, 2002. Ou SX, Han D, Severson RK, Chen Z, Neglia JP, Reaman GH, Buckley JD, Robison LL. Birth characteristics, maternal reproductive history, hormone use during pregnancy, and risk of childhood acute lymphocytic leukemia by immunophenotype United States ; . Cancer Causes Control 13 1 ; : 15-25, 2002. Heerema NA, Sather HN, Sensel MG, La MK, Hutchinson RJ, Nachman JB, Reaman GH, Lange BJ, Steinherz PG, Bostrom BC, Gaynon PS, Uckun FM. Abnormalities of chromosome bands 15q13-15 in childhood acute lymphoblastic leukemia. Cancer 94 4 ; : 1102-10, 2002. Kurre HA, Ettinger, AG, Veenstra, DL, Gaynon PS, Franklin J, Sencer SF, Reaman GH, Lange BJ, Holcenberg JS. A pharmacoeconomic analysis of pegaspargase versus native Escherichia coli Lasparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia. J Pediatr Hematol Oncol 24 3 ; : 175-81, 2002. Abu-Ghosh AM, Krailo MD, Goldman SC, Slack RS, Davenport V, Morris E, Laver JH, Reaman GH, Cairo MS. Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms' tumor. Ann Oncol 13 3 ; : 460-9, 2002. Avramis VI, Sencer S, Periclou AP, Sather H, Bostrom BC, Cohen LJ, Ettinger AG, Ettinger LJ, Franklin J, Gaynon PS, Hilden JM, Lange B, Majlessipour F, Mathew P, Needle M, Neglia J, Reaman G, Holcenberg JS, Stork L. A randomized comparison of native Excherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard risk-acute lymphoblastic leukemia. Blood 99 6 ; : 1986-94, 2002. Gilbert MR, Friedman HS, Kuttesch JF, Prados MD, Olson JJ, Reaman GH, Zaknoen SL. A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant Glioma before radiation therapy. Neuro-oncol 4 ; : 261-7, 2002. Steinherz PG, Seibel NL, Ames MM, Avramis VI, Krailo MD, Liu-Mares W, Reid JM, Safrgren SL, Reaman GH. Phase I Study of Gemcitabine Difluorodeoxycytidine ; in Children with Relapsed or Refractory Leukemia. Leukemia & Lymphoma 43 10 ; : 1945-1950, 2002. Wen W, Shu XO, Potter JD, Severson RK, Buckley JD, Reaman GH, Robison LL. Parental medication use and risk of childhood acute lymphoblastic leukemia. Cancer 95 8 ; : 1786-94, 2002. Reaman GH. Pediatric oncology: current views and outcomes. Pediatr Clin North 49 6 ; : 1305-18, 2002. Liu L, Krailo M, Reaman GH, Bernstein L. Surveillance, Epidemiology and End Results Childhood Cancer Linkage Group. Childhood cancer patients' access to cooperative group cancer programs. Cancer 97 5 ; : 1339-45, 2003. Anderson BD, Smith MA, Reaman GH, Kodish ED. Views of American oncologists about the purposes of clinical trials. J Natl Cancer Inst 95 8 ; : 630-1, 2003. Bhatia S, Yasui Y, Robison LL, Birch JM, Bogue MK, Diller L, DeLaat C, Fossati-Bellani F, Morgan E, Oberlin O, Reaman G, Ruymann FB, Tersak J, Meadows AT. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease. J Clin Oncol 21 23 ; : 4386-94, 2003. Byrne J, Fears TR, Mills JL, Zeltzer LK, Sklar C, Meadows AT, Reaman GH, Robison LL. Fertility of long-term male survivors of acute lymphoblastic leukemia diagnosed during childhood. Pediatr Blood Cancer. 42 4 ; : 364-72, 2004. Lang Z, Dinndorf P, Ladisch S, Bayever E, Reaman G. Chromosomal transformation in donor cells following allogeneic bone marrow transplantation. Bone Marrow Transplant 33 12 ; : 1253-1256, 2004.
More than 4 to 6 hours. Some babies need to eat even more often. It is important that babies be fed during the night. They need to be woken to eat if they do not wake up on their own. Young children with MCAD may need to have a starchy snack such as bread, cereal, rice ; before bed and another during the night. They may need another snack first thing in the morning. Your dietitian can give you ideas for good night-time snacks. Dietitians know what are the correct foods to eat. Most teens and adults with MCAD can go without food for up to 12 hours without problems when they are well. They need to continue the other treatments for life and gemtuzumab.
Prolapse and complete right bundle branch block. During the arrhythmia episodes no other precipitating factors were Background: Gemcitabine is an antimetabolic drug for solid reported. The close temporal relationship of the arrhythmia to tumors. Altough its pharmacokinetics as well as its side-effects drug administration and the recurrence of arrhythmia upon are well known, paroxysmal atrial fibrillation associated to the rechallenge allowed to hypothesize an intrinsic pro-arrhythmic effect of gemcitabine or its metabolite 2', 2'-difluorodeoxyadministration of this drug has not yet been described. Patients and methods: We describe the case of a 78-year-old uridine. Conclusions: The occurrence of atrial fibrillation during the man with pancreatic adenocarcinoma who presented repeated paroxysmal atrial fibrillation episodes 18-24 hours after every administration of gemcitabine may be considered as a cardiac gemcitabine infusion which resolved with antiarrhythmic arrhythmia drug-related toxicity. This side-effect of gemcitadrugs. This clinical history was positive for a remote brief bine infusion is a previously unreported sign of drug toxicity; episode of atrialfibrillation, which resolved spontaneously, and therefore, a high level of awareness to this problem is warthe patient had no predisposing factors for supraventricular ranted when this drug is administered. arrhythmias systemic hypertension, diabetes or coronary artery disease ; . Key words: cardiac toxicity, gemcitabine, paroxysmal atrial Results: Cardiac work-up revealed only a mild mitral-valve fibrillation.
Gemcitabine vesicant
Channels, with blockers of these channels eliminating some in vitro rhythms and hypoxiainduced gasping in vivo and in situ 13, 27 ; . Also eliminated was a "non-gasping" rhythm of an in situ preparation having a brainstem transection at the pontomedullary junction 14 ; . This "non gasping" rhythm differs dramatically from eupnea recorded in a preparation having an intact pons since there is a marked alteration in the shape and amplitude of the inspiratory burst as well as a loss of post-inspiratory discharge 1, 24, 25 ; . For in situ preparations having an intact pons or in conscious rats, blockade of persistent sodium channels did not eliminate eupnea 25 and gemzar.
Gemcitabine oxaliplatin thrombocytopenia
Available evidence, data synthesis, clinical interpretation, and recommendations and will be used by the DQTCSOS to make funding and policy recommendations. III. METHODS This advice report, produced by the PEBC's Gastrointestinal Cancer DSG, is a convenient and up-to-date source of the best available evidence on the role of gemcitabine in the treatment of gallbladder cancer developed through systematic reviews of the available evidence. Members of the DSG disclosed any potential conflicts of interest. The PEBC is editorially independent of Cancer Care Ontario and the Ontario Ministry of Health and Long-Term Care. The PEBC has a formal standardized process to ensure the currency of each clinical guidance report. This process consists of the periodic review and evaluation of the scientific literature and, where appropriate, integration of this literature with the original clinical guidance report information. Literature Search Strategy The MEDLINE database was searched from 1996 to March week 2 ; 2005. The following Medical subject headings MeSH ; "gemcitabine" and "gallbladder neoplasms" were combined, and results were limited to English only. In addition, conference proceedings from the 1998-2004 meetings of the American Society of Clinical Oncology were searched for abstracts of relevant trials, including the 2004 Gastrointestinal Cancers Symposium abstracts. The Canadian Medical Association Infobase : mdm cpgsnew cpgs index ; and the National Guidelines Clearinghouse : guideline.gov index ; were also searched for existing evidence-based practice guidelines. An additional article not found in the literature search, as it was too recent to be indexed, was obtained from a Gastrointestinal Cancer DSG member. Relevant articles and abstracts were selected and reviewed by two reviewers, and the reference lists from those sources were searched for additional trials. Inclusion Criteria Articles were selected for inclusion in the systematic review of the evidence if they were fully published English-language reports or published abstracts of: 1. Randomized controlled trials RCTs ; comparing gemcitabine, either alone or in combination, with best supportive care or other therapy in the treatment of cholangiocarcinoma or gallbladder cancer. 2. Phase II trials reporting on the efficacy or adverse effects detected in treatment with gemcitabine, alone or in combination, in the treatment of cholangiocarcinoma or gallbladder cancer. Exclusion Criteria 1. Letters and editorials were not eligible. Synthesizing the Evidence As none of the trials obtained were RCTs, no pooling of outcome data was possible.
Gemcitabine for the treatment of metastatic breast cancer and genotropin.
Gemcitabine ts-1
Our retrospective study assessed the efficacy and safety of a modified IFL regimen in Japanese patients with previously untreated metastatic colorectal cancer. The patient baseline characteristics in this study were similar compared with Western studies except for the incidence of prior adjuvant chemotherapy. The incidence of adjuvant chemotherapy was lower, not only in this study, but also in another Japanese study 4 5% ; , as compared with an incidence of 11 28% in Western countries 3, 8 13 ; . This difference might influence the clinical outcome, because the overall response rate 48% ; was higher than originally reported in the United States 39% ; , but similar to those reported in Japan 44 69% ; 3, 10, 11 ; . The toxicity profile for the regimen, especially the lower incidence of diarrhea, might be notable in comparison with either original or reduced-dose IFL regimens. Although there are limitations in comparing the results of different studies and our findings were based on a retrospective analysis in the single institution, one of the potential reasons for the difference in the incidence of diarrhea of this regimen is.
As it is almost impossible to obtain agreement on what it is that defines a man with LUTS BPH, it seems logical to say that progression cannot be defined in terms of a transition from non-cases to cases. Instead, progression must be measured by documenting deterioration in any number of physiological variables that we associate with the LUTS BPH syndrome. Traditionally these have included the following: 1. Decrease in maximum flow rate 2. Increase in residual volume 3. Increase in prostate size 4. Deterioration increase ; in symptom score. In addition, definable events, such as the occurrence of acute urinary retention or prostate surgery, have been used. Less commonly, changes in urodynamic variables and deterioration in disease-specific quality of life have been advocated. Considerable interest currently rests with PSA. It appears to be as good a predictor of progression as any of the variables mentioned above. 1.2.1 Indicators of progression and gentamicin.
Richard Jury embarks on the darkest investigation of his career when the dead body of a young London girl leads to the cold case of a missing girl in Launceston -- an unsolved mystery that has haunted Police Officer Brian Macalvie for years. A five-week New York Times bestseller in hardcover. Hit other major bestseller lists include: USA Today, Wall Street Journal, Washington Post, Chicago Tribune, and Publishers Weekly. 0-451-21696-2 .99 Signet Mass Market.
Trol eyes were observed at 300-mol L intracameral H-7 or at 300- or 600-mol L intravitreal H-7 Figure 5, E-H ; . At 1.2-mmol L intravitreal H-7, a physiologically minimal but statistically significant difference was observed only at 40 and 45 minutes after intramuscular administration of pilocarpine, with the H-7treated eyes accommodating around 1 diopter D ; less than the controls Figure 5, H ; . CLINICAL EXAMINATION Mild punctate corneal epithelial defects and slight epithelial cloudiness were seen in H-7treated eyes compared with controls 2 hours after 150-mmol L 1.1-mg ; topical H-7 or vehicle. No AC, lens, or retinal abnormalities were seen at any time following topical, intracameral, or intravitreal administration of H-7 or vehicle and gentian.
INTRODUCTION Expression of the genes encoding digestive enzymes in the acinar pancreas has been used as a model for tissue-specific gene expression. Work performed over the past few years from a number of laboratories has resulted in the description of nucleotide sequences within the acinar-specific genes which bind tissue-specific factors including pancreas-specific transcription factor 1 PTFl ; 1 ; pancrease-specific factor Pan ; 2 ; and exocrine pancreas transcription factor 1 XPF-1 and gemcitabine.
Cence values were used for individual experiments. Fig. 4a shows that, for untreated cells, although the median level is around zero, there are several cells with negative fluorescence values. This phenomenon was often observed for the untreated cells and lower doses, and reflects the way in which the image analysis procedures were carried out. The integrated green fluorescence value associated with the DNA from each cell was calculated after subtraction of the back and ginger.
In vivo tests were performed under the Home Office Animals Scientific Procedures ; Act 1986. The rodent malaria lines used were Plasmodium berghei NY drug-susceptible ; , P. berghei P primaquine-resistant ; , P. berghei KFY sulfadoxine pyrimethamine-resistant ; , Plasmodium yoelii NS chloroquine-resistant ; , P. yoelii ART artemisinin-resistant ; and Plasmodium chabaudi AS drug-susceptible ; . Swiss outbred 20 g male Tuck Farmed White TFW ; albino mice A. Tuck and Son, Rayleigh, Essex, UK ; were kept in specific pathogen-free conditions and fed ad libitum with SDS RM3 expanded diet supplied by Special Diet Services, Witham, Essex, UK ; . For subcutaneous administration, artemisone and artesunate were dissolved in 10% DMSO 0.05% Tween 80 Sigma ; in distilled water. For oral administration, compounds were dissolved in standard suspending formula [0.5% sodium carboxymethylcellulose 0.5% benzyl alcohol 0.4% Tween 80 0.9% NaCl all Sigma ; ]. Mice were infected intravenously with 2 106 infected red cells and treated subcutaneously or orally with 0.2 mL of a solution of the test compounds 2 h day 0 ; and on days 1, 2 and 3 post-infection. Parasitaemia was determined by microscopic examination of Giemsa-stained blood films taken on day 4. Microscopic counts of blood films from each mouse were processed using GraphPad Prism 4 GraphPad Software, Inc., CA, USA ; and expressed as percentages of inhibition from the arithmetic mean parasitaemias of each group in relation to the untreated group. Dose response curves were obtained and ED50 and ED90 values calculated. The degree of cross-resistance was determined by comparing the activity in the parent and resistant lines using the following formula: Index of cross-resistanceI 50 90 ED50 ED90 resistant line ED50 ED90 parent line.
2. Testing for what levels are a good indicator of a perimenopausal phase? a. b. c. estrogen follicle stimulating hormone progesterone blood pressure and ginkgo.
Doxorubicin alone in disseminated metastatic recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. J Clin Oncol 2000; 18: 2385-2394. Heidemann E, Stoeger H, Souchon R et al. Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial. Ann Oncol 2002; 13: 1717-1729. Sledge GW, Neuberg D, Ingle J et al. Phase III trial of doxorubicin, paclitaxel and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer MBC ; : an Intergroup trial E1193 ; . J Clin Oncol 2003; 21: 588-592. A'Hern RP, Smith IE, Ebbs SR. Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens. Br J Cancer 1993; 67: 801-805. Downloaded from TheOncologist by on March 25, 2008 62 Findlay BP, Walker-Dilks C. Epirubicin, alone or in combination chemotherapy, for metastatic breast cancer. Provincial Breast Cancer Disease Site Group and the Provincial Systemic Treatment Disease Site Group. Cancer Prev Control 1998; 2: 140-146. French Epirubicin Study Group. A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. J Clin Oncol 1991; 9: 305-312. French Epirubicin Study Group. Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment. J Clin Oncol 2000; 18: 3115-3124. Bernard-Marty C, Cardoso F, Piccart MJ. Use and abuse of taxanes in the management of metastatic breast cancer. Eur J Cancer 2003; 39: 1978-1989. Sjstrm J, Blomqvist C, Mouridsen H et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 1999; 35: 1194-1201. Bonneterre J, Roche H, Monnier A et al. Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer 2002; 87: 1210-1215. O'Shaughnessy J, Nag S, Calderillo-Ruiz G et al. Gemcitabine plus paclitaxel versus paclitaxel as first-line treatment for anthracycline pre-treated metastatic breast cancer: interim results of a global phase III study. Proc Soc Clin Oncol 2003; 22: 7. Chan S, Friedrichs K, Noel D et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999; 17: 2341-2354. Paridaens R, Biganzoli L, Bruning P et al. Paclitaxel versus doxorubicin as first line single-agent chemotherapy for metastatic breast cancer: A European Organization for Research and Treatment of Cancer randomized study with cross-over. J Clin Oncol 2000; 18: 724-733 and gemifloxacin.
Characteristics. Hematologic Malignancies The clinical value of tumor burden at diagnosis in Hodgkin lymphoma p ; Paolo G. Gobbi, Chiara Broglia, Giuseppe Di Giulio, Monica Mantelli, Paola Anselmo, Francesco Merli, Pier L. Zinzani, Gabriele Rossi, Vincenzo Callea, Emilio Iannitto, Marco Paulli, Lorena Garioni, Edoardo Ascari In this study, the authors found that the tumor burden present at diagnosis in patients with Hodgkin lymphoma could be measured even retrospectively ; from a careful evaluation of the staging computed tomography scans. The predictive power of this measured tumor burden was very strong, in that it had greater predictive power compared with each of the hitherto tested, single prognostic factors and multiple indices; moreover, definite and specific limits of tumor burden seemed to emerge for the effectiveness of some treatment protocols. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: A Phase II study by the National Cancer Institute of Canada Clinical Trials Group NCIC-CTG ; Michael Crump, Tara Baetz, Stephen Couban, Andrew Belch, Deborah Marcellus, Kang Howson-Jan, Kevin Imrie, Robert Myers, Grenfell Adams, Keyue Ding, Nancy Paul, Lois Shepherd, Jose Iglesias, Ralph Meyer In the current study, gemcitabine 1000 mg m2 intravenously [i.v.] on Days 1 and 8 ; , dexamethasone 40 mg orally on Days 1-4 ; , and cisplatin 75 mg m2 i.v. on Day 1 ; was an active regimen in B-cell non-Hodgkin lymphoma and was administered with acceptable toxicity to outpatients. A Phase III trial comparing this regimen with standard cisplatin-based chemotherapy is now ongoing through the National Cancer Institute of Canada Clinical Trials Group. Neuro-Oncology Late-delayed cerebral involvement in systemic non-Hodgkin lymphoma: A second primary tumor or a tardy recurrence? p ; Alexander Lossos, Yaqoub Ashhab, Elena Sverdlin, Gail Amir, Dina Ben-Yehuda, Tali Siegal Using comparative analysis of the immunoglobulin heavy chain variable region gene rearrangement, the authors showed that some instances of late-delayed central nervous system involvement in B-cell non-Hodgkin lymphoma may represent a second new lymphoma rather than a true recurrence of the original systemic tumor. Discipline Diagnostic Imaging The age at which women begin mammographic screening James A. Colbert, Emily M. Kaine, JudyAnn Bigby, Darrell N. Smith, Richard H. Moore, Elizabeth Rafferty, Diane Georgian-Smith, Helen and ginseng.
Gemcitabine medicine
Gemcitabbine, gemcitabone, gemcitahine, temcitabine, gemcitsbine, gsmcitabine, gemcitabind, gemc9tabine, gemfitabine, gemcitabije, gemcitxbine, gemcitabin, gemcitaibne, yemcitabine, vemcitabine, gemcitabin3, gemcitbaine, gemcitabihe, gekcitabine, gemcitagine, gemciitabine, g4mcitabine, gemcifabine, egmcitabine, gemcitabiine, emcitabine, grmcitabine, gemctabine, gemcitanine, gemctiabine, gemditabine, gemmcitabine, gecmitabine, gemcitwbine, gdmcitabine, gemcitabime, gemcltabine, gemictabine, gemc8tabine, gemcitabne, gemcihabine, gemxitabine, hemcitabine, bemcitabine, gemcitaabine, gemcittabine.
Gemcitabine data sheet
Gemcitabine vesicant, gemcitabine oxaliplatin thrombocytopenia, gemcitabine ts-1, gemcitabine medicine and gemcitabine data sheet. Order generic gemcitabine online, gemcitabine hair loss, gemcitabine resistance pancreatic cancer and gemcitabine toxicity or gemcitabine leiomyosarcoma.
|
